Sandoz moves to dismiss amended antitrust claims from US state plaintiffs over generic drugs
( May 6, 2026, 23:23 GMT | Official Statement) -- MLex Summary: Sandoz asked a US federal judge to dismiss US state plaintiffs’ amended US antitrust claims over generic drugs. Sandoz said that the new complaint only parrots price-fixing allegations from dozens of other complaints already proceeding in the sprawling multidistrict antitrust litigation, and it fails to plead viable claims against the Swiss company. Sandoz moved to dismiss based on a lack of jurisdiction and timeliness. See attached file....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.